Yiming Zhou

发表

Identification of early growth response protein 1 (EGR-1) as a novel target for JUN-induced apoptosis in multiple myeloma.

F. Zhan, B. Barlogie, J. Shaughnessy, 2010, Blood.

Degradation of hexavalent chromium and methyl orange by the synergistic system of graphitic carbon nitride and electron beam irradiation.

Yiqing Wu, Zhengyan Wu, Yiming Zhou, 2022, Chemosphere.

Proliferation is a central independent prognostic factor and target for personalized and risk-adapted treatment in multiple myeloma

Axel Benner, John D. Shaughnessy, Thomas Hielscher, 2011, Haematologica.

TP53 deletion is not an adverse feature in multiple myeloma treated with total therapy 3

B. Barlogie, J. Shaughnessy, E. Anaissie, 2009, British journal of haematology.

Prediction of cytogenetic abnormalities with gene expression profiles.

O. Stephens, B. Barlogie, J. Shaughnessy, 2012, Blood.

Pharmacogenomics of bortezomib test-dosing identifies hyperexpression of proteasome genes, especially PSMD4, as novel high-risk feature in myeloma treated with Total Therapy 3.

John Crowley, Pingping Qu, Bart Barlogie, 2011, Blood.

High-risk myeloma is associated with global elevation of miRNAs and overexpression of EIF2C2/AGO2

David R Williams, Bart Barlogie, O. Stephens, 2010, Proceedings of the National Academy of Sciences.

An intermediate-risk multiple myeloma subgroup is defined by sIL-6r: levels synergistically increase with incidence of SNP rs2228145 and 1q21 amplification.

O. Stephens, B. Barlogie, J. Shaughnessy, 2012, Blood.

Gene expression profiling of plasma cells at myeloma relapse from tandem transplantation trial Total Therapy 2 predicts subsequent survival.

B. Barlogie, J. Shaughnessy, E. Anaissie, 2009, Blood.

Targeting angiogenesis via a c-Myc/hypoxia-inducible factor-1alpha-dependent pathway in multiple myeloma.

G. Tonon, S. Lababidi, D. Chauhan, 2009, Cancer research.

Cytogenetic abnormalities in multiple myeloma: poor prognosis linked to concomitant detection in random and focal lesion bone marrow samples and associated with high‐risk gene expression profile

B. Barlogie, E. Anaissie, F. van Rhee, 2009, British journal of haematology.

The role of fibroblast growth factor 18 in cancers: functions and signaling pathways

Yiming Zhou, Q. You, Tao Ling, 2023, Frontiers in Oncology.

Proliferation is a central independent prognostic factor and target for personalized and risk-adapted treatment in multiple myeloma

T. Rème, J. Rossi, B. Klein, 2011, Haematologica.